证券代码：301103 证券简称：何氏眼科 公告编号：2024-036 辽宁何氏眼科医院集团股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决提案的情况。 2.本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2024 年第二次临 时股东大会于 2024 年 9 月 19 日召开，公司董事会已于 2024 年 8 月 30 日在巨潮 资讯网上刊登了《关于召开 2024 年第二次临时股东大会的通知公告》。 本次股东大会由公司董事会召集，现场会议由公司董事长何伟先生主持，会 议的召集、召开符合《公司法》、《上市公司股东大会规则》、《深圳证券交易所创 业板股票上市规则》及《公司章程》等规定。 1.会议召开方式：本次股东大会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间： 现场会议时间为：2024 年 9 月 19 日（星期四）14:00 截至本次股东大会股权登记日，公司总股本为 15 ...

北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2024 年第二次临时股东大会的 法律意见书 2024 年 9 月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2024 年第二次临时股东大会的 法律意见书 致：辽宁何氏眼科医院集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受辽宁何氏眼科医院集团股份 有限公司（以下简称"公司"）委托，指派本所律师对公司 2024 年第二次临时股 东大会（以下简称"本次股东大会"）的 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东大会届次：2024 年第二次临时股东大会 2.会议召集人：辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）董 事会 3.会议召开的合法、合规性：2024 年 8 月 28 日，公司第三届董事会第八次 会议审议通过了《关于召开 2024 年第二次临时股东大会的议案》。同意召开本次 股东大会。本次会议的召集程序符合有关法律法规、深圳证券交易所业务规则及 公司章程的规定。 4.会议召开的日期、时间： 证券代码：301103 证券简称：何氏眼科 公告编号：2024-035 辽宁何氏眼科医院集团股份有限公司 关于召开 2024 年第二次临时股东大会的通知 5.会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 本次股东大会将通过深圳证券交易所交易系统和互联网投票系统向公司股东提 供网络形式的投票平台，公司股东可以在网络投票时间内通过深圳证券交易所交 易系统或互联网投票系统对本次股东大会审议事项进行投票表决。公司股东只能 选择现场投票、网络投票中的一种表决方式。如同一股东账户 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2024-033 辽宁何氏眼科医院集团股份有限公司 关于使用部分闲置募集资金（含超募资金） 及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第八次会议、第三届监事会第八次会议，审议通过了《关于 使用部分闲置募集资金（含超募资金）及自有资金进行现金管理的议案》，在不 影响募投项目投资建设和保证募集资金安全使用的情况下，以及为提高公司资金 使用效率、合理利用闲置自有资金，同意公司使用部分闲置募集资金（含超募资 金）不超过人民币 70,000 万元及自有资金不超过人民币 70,000 万元进行现金管 理，用于购买安全性高、流动性好、满足保本要求的理财产品，使用期限自股东 大会审议通过之日起不超过十二个月内有效，如单笔交易的存续期超过了决议有 效期，则决议有效期自动延续至单笔交易到期时止。在上述使用期限及额度内， 资金可以循环滚动使用。现将相关事宜公告如下： 一、募集资金基本情况 经中 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Item%201%20Important%20Notice,%20Table%20of%20Contents%20and%20Definitions) The board and supervisors confirm the report's accuracy, with no cash dividends or bonus shares planned for the half-year - The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of the report, assuming legal responsibility; all directors attended the board meeting to review this semi-annual report[2](index=2&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the 2024 half-year period[2](index=2&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Item%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's basic information, key financial performance, and non-recurring gains and losses [Company Basic Information](index=6&type=section&id=I.%20Company%20Profile) This section provides the company's basic business registration information, including stock abbreviation 'He Eye Specialist', stock code '301103', listing exchange, and legal representative Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | He Eye Specialist | | Stock Code | 301103 | | Listing Exchange | Shenzhen Stock Exchange | | Company Chinese Name | Liaoning He Eye Specialist Hospital Group Co., Ltd. | | Legal Representative | He Wei | [Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company's performance significantly declined, with operating revenue at **RMB 585 million**, a **5.84% year-on-year decrease**, and net profit attributable to shareholders at **RMB 24.06 million**, a **69.29% year-on-year decrease** Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 584,757,474.76 | 620,995,594.44 | -5.84% | | Net Profit Attributable to Shareholders (RMB) | 24,063,967.54 | 78,347,857.61 | -69.29% | | Net Profit Attributable to Shareholders Excluding Non-Recurring Items (RMB) | 24,356,076.26 | 74,360,395.21 | -67.25% | | Net Cash Flow from Operating Activities (RMB) | 99,776,720.00 | 111,264,837.73 | -10.33% | | Basic Earnings Per Share (RMB/share) | 0.1535 | 0.4958 | -69.04% | | Weighted Average Return on Net Assets | 1.17% | 3.58% | -2.41% | | **Indicator** | **Current Period End** | **Prior Year End** | **Year-on-Year Change** | | Total Assets (RMB) | 2,417,992,248.54 | 2,483,695,372.45 | -2.65% | | Net Assets Attributable to Shareholders (RMB) | 2,036,002,056.42 | 2,075,313,837.01 | -1.89% | [Non-Recurring Gains and Losses](index=7&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **RMB -0.29 million**, primarily comprising **RMB 1.59 million** in government grants and **RMB -1.96 million** in other non-operating income and expenses Non-Recurring Gains and Losses Items | Item | Amount (RMB) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 25,105.48 | | Government Grants Included in Current Profit/Loss | 1,585,802.86 | | Other Non-Operating Income and Expenses Apart from the Above | -1,964,820.81 | | Less: Income Tax Impact | -65,157.91 | | Minority Interests Impact (After Tax) | 3,354.16 | | **Total** | **-292,108.72** | [Management Discussion and Analysis](index=9&type=section&id=Item%203%20Management%20Discussion%20and%20Analysis) This section provides an overview of the company's operations, core competencies, financial performance, investment activities, and key risks [Company Business and Operations Overview](index=9&type=section&id=I.%20Main%20Businesses%20During%20the%20Reporting%20Period) In the first half of 2024, the company focused on strengthening brand building, optimizing industrial layout, and increasing technological innovation investments amidst declining consumer demand and intensifying market competition, while advancing digital transformation to enhance service efficiency - The company is a group-based service institution integrating medical, educational, and research functions, adopting a three-tier eye health service model focused on lifelong eye health management, with **123 eye care service institutions** as of the reporting period end[26](index=26&type=chunk) - Key business development focuses include optimizing traditional business structure towards high-value consumer medical projects, expanding optometry services primarily within Liaoning province, and advancing digital transformation through 'Digital Bright City' initiatives for online services, big data, and smart equipment upgrades[27](index=27&type=chunk) - The company employs a three-tier eye health service model, integrated with centralized procurement and group control management, continuously optimizing its operating model through digital transformation, including developing an 'Healthcare + Internet' OMO model and enhancing digital marketing[29](index=29&type=chunk)[32](index=32&type=chunk)[34](index=34&type=chunk) [Core Competitiveness Analysis](index=15&type=section&id=II.%20Core%20Competitiveness%20Analysis) The company's core competitiveness stems from its unique three-tier eye health service model, pioneering advantages in gene therapy, integrated medical-educational-industrial-academic-research platform, digital transformation, strong R&D conversion capabilities, and established brand reputation through social welfare and academic activities - **Three-tier eye health medical service advantage**: Established a replicable standardized ophthalmology chain process, extending this model nationwide through internet hospitals and big data platforms[37](index=37&type=chunk) - **Technology and innovation advantage**: Leveraging Hainan Boao Lecheng pilot zone policies to conduct internationally advanced gene therapy and drug clinical applications, while digital transformation enhances personalized and precise diagnosis and treatment[38](index=38&type=chunk)[41](index=41&type=chunk) - **Research and talent advantage**: Actively conducting clinical application research based on national-level platforms, with **11 papers published** in the first half of 2024, and collaborating with multiple universities to cultivate master's and doctoral students, ensuring high-quality talent supply[42](index=42&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk) - **Brand and human resource advantage**: Brand reputation steadily improved through international academic conferences and public welfare activities; the company has **70 national and provincial/municipal society members** and a comprehensive talent development system[43](index=43&type=chunk)[44](index=44&type=chunk)[46](index=46&type=chunk) [Main Business Analysis](index=17&type=section&id=III.%20Main%20Business%20Analysis) During the reporting period, the company's main business revenues generally declined, with cataract and other eye disease treatment services seeing significant drops of **16.04%** and **19.54%** respectively, while non-surgical treatment was the only segment to grow by **7.23%** Main Business Revenue and Gross Margin by Segment | By Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Refractive Surgery Correction Services | 131,073,193.44 | 66,311,668.54 | 49.41% | -5.29% | -3.14% | -1.12% | | Cataract Treatment Services | 93,051,160.77 | 51,588,477.28 | 44.56% | -16.04% | -15.19% | -0.55% | | Vitreoretinal Treatment Services | 46,080,305.67 | 32,523,126.76 | 29.42% | -2.57% | 0.35% | -2.06% | | Other Eye Disease Treatment Services | 21,301,231.34 | 10,517,181.32 | 50.63% | -19.54% | -15.66% | -2.27% | | Non-Surgical Treatment | 111,488,060.37 | 77,355,421.78 | 30.62% | 7.23% | 11.57% | -2.70% | | Optometry Services | 178,183,802.68 | 99,128,790.37 | 44.37% | -6.75% | 1.71% | -4.62% | - The company's expenses generally increased, with sales and administrative expenses rising by **12.94%** and **12.37%** year-on-year respectively, while R&D investment grew by **35.69%** due to an increase in research projects[48](index=48&type=chunk) [Assets and Liabilities Analysis](index=19&type=section&id=V.%20Assets%20and%20Liabilities%20Analysis) As of the reporting period end, total assets were **RMB 2.42 billion**, a **2.65% decrease** from the prior year-end, with fixed assets increasing their proportion due to property acquisition, and **RMB 1.45 million** in restricted cash - Fixed assets increased by **2.44 percentage points** compared to the prior year-end, primarily due to the acquisition of real estate by Dalian Advanced Branch Hospital[51](index=51&type=chunk) - As of the reporting period end, **RMB 1.45 million** in monetary funds had restricted use, mainly for e-commerce platform deposits and bank guarantees[52](index=52&type=chunk) [Investment Analysis](index=19&type=section&id=VI.%20Investment%20Analysis) During the reporting period, the company had no significant equity or non-equity investments; of the **RMB 1.16 billion** IPO proceeds, **RMB 455 million** has been used, with **RMB 725 million** remaining, and some projects underperforming due to incubation, construction delays, or policy changes Raised Funds Utilization | Item | Amount (RMB Million) | | :--- | :--- | | Total Raised Funds | 1,164.31 | | Funds Invested in Current Period | 40.23 | | Total Funds Invested Cumulatively | 454.81 | | Unused Raised Funds Balance | 725.22 | - Some raised fund projects did not meet expected benefits due to: **Beijing and Chongqing new hospital projects** being in incubation and incurring personnel and brand building costs; **Liaoning Ruimu Commercial New Project** experiencing business delays due to central warehouse construction slowdown; and **Hainan Cross-border E-commerce Project** facing lower-than-expected international product sales due to stricter regulatory policies[57](index=57&type=chunk) [Analysis of Major Holding and Participating Companies](index=25&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) During the reporting period, Shenyang He Eye Specialist Hospital Co., Ltd. was the primary profit contributor, with other key subsidiaries also generating significant net profits, and recent subsidiary changes having no material impact on overall performance Net Profit Contribution from Major Subsidiaries | Company Name | Net Profit (RMB) | | :--- | :--- | | Shenyang He Eye Specialist Hospital Co., Ltd. | 46,705,137.16 | | Shenyang Ailuo Commercial Co., Ltd. | 19,032,286.82 | | Dalian He Eye Optometry Technology Co., Ltd. | 8,572,435.71 | | Huludao He Eye Specialist Hospital Co., Ltd. | 4,682,642.18 | | Anshan He Eye Specialist Hospital Co., Ltd. | 4,263,096.33 | | Dalian He Eye Specialist Hospital Co., Ltd. | 4,217,715.90 | - During the reporting period, the company established **6 new subsidiaries**, including Youguang International Group (Hong Kong) Co., Ltd. and Hainan Dragonfly Health Technology Co., Ltd., and deregistered Shenzhen He Eye Specialist Clinic, with these changes having no significant impact on overall operations or performance[66](index=66&type=chunk) [Risks and Countermeasures](index=26&type=section&id=X.%20Risks%20and%20Countermeasures) The company faces key risks including changes in industry regulatory policies, intensifying market competition, and potential talent loss or shortage, which it addresses by closely monitoring policies, strengthening competitive advantages, and improving human resource strategies - **Industry regulatory policy change risk**: The medical service industry is strictly regulated in market access and medical insurance settlement, and policy changes may adversely affect business development[67](index=67&type=chunk) - **Market competition risk**: As the number of private ophthalmology specialty hospitals increases, industry competition intensifies, and the company will face significant competitive pressure if it cannot maintain and strengthen its competitive advantages[69](index=69&type=chunk) - **Talent loss and shortage risk**: Excellent doctors and management teams are crucial for medical institution development, and talent loss or insufficient talent growth relative to business expansion will adversely affect the company's development[70](index=70&type=chunk) [Corporate Governance](index=28&type=section&id=Item%204%20Corporate%20Governance) This section details changes in the company's senior management and the termination of its equity incentive plan [Changes in Directors, Supervisors, and Senior Management](index=28&type=section&id=II.%20Changes%20in%20Company%20Directors,%20Supervisors,%20and%20Senior%20Management) During the reporting period, Ms. Deng Ming ceased to be the CFO due to management restructuring but retains other roles, while Mr. He Yuehua was appointed as the new CFO Changes in Senior Management | Name | Position Held | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Deng Ming | CFO | Dismissal | 2024年04月01日 | No longer serves as CFO due to company management needs and division of labor adjustment | | He Yuehua | CFO | Appointment | 2024年04月01日 | Board of Directors approved the appointment of Mr. He Yuehua as the company's CFO | [Equity Incentive and Employee Stock Ownership](index=28&type=section&id=IV.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans,%20Employee%20Stock%20Ownership%20Plans,%20or%20Other%20Employee%20Incentive%20Measures) During the reporting period, the company terminated its 2023 Restricted Stock Incentive Plan, invalidating all granted but unvested restricted shares, with no other employee incentive measures disclosed as ongoing - On April 1, 2024, the company's board and supervisory board approved a resolution to terminate the 2023 Restricted Stock Incentive Plan, rendering all remaining granted but unvested restricted shares void[75](index=75&type=chunk)[76](index=76&type=chunk) [Environmental and Social Responsibility (ESG)](index=30&type=section&id=Item%205%20Environmental%20and%20Social%20Responsibility) This section outlines the company's environmental protection measures and its active fulfillment of social responsibilities through various public welfare initiatives [Environmental Protection](index=30&type=section&id=I.%20Significant%20Environmental%20Issues) The company and its subsidiaries are not designated as key polluting units and received no environmental administrative penalties during the reporting period, ensuring compliant treatment of wastewater, solid waste, and exhaust gas - The company and its subsidiaries are not classified as key polluting units and have no record of environmental administrative penalties during the reporting period[77](index=77&type=chunk) [Social Responsibility](index=30&type=section&id=II.%20Social%20Responsibility) During the reporting period, the company actively fulfilled its social responsibilities by focusing on eye health for the elderly and children, conducting nationwide charitable eye health services, leveraging technology for smart eye health management, and continuously training grassroots doctors to support rural revitalization - **Care for the elderly and children**: Conducted public welfare projects in multiple locations nationwide, such as establishing 'Myopia Prevention and Control Monitoring Stations' in schools and providing free eye health screenings and treatments for rural children and the elderly[79](index=79&type=chunk)[80](index=80&type=chunk) - **Technology + Public Welfare**: Advancing the construction of 'Digital Bright City' by utilizing AI intelligent diagnosis and smart eye health management stations to bridge the 'last mile' of eye health management[82](index=82&type=chunk)[83](index=83&type=chunk) - **Training grassroots doctors**: As a National Health Commission training base for blindness prevention and treatment, the company has cumulatively trained over **50,000 grassroots doctors** and eye health management personnel, enhancing grassroots medical service levels[84](index=84&type=chunk) [Significant Matters](index=33&type=section&id=Item%206%20Significant%20Matters) This section addresses the company's litigation status, administrative penalties received by subsidiaries, and the absence of significant related party transactions during the reporting period [Litigation Matters](index=34&type=section&id=VIII.%20Litigation%20Matters) During the reporting period, the company had no significant litigation or arbitration matters, with **7 minor lawsuits** totaling **RMB 0.54 million** that are not expected to have a material impact - The company had no significant litigation or arbitration matters during this reporting period[87](index=87&type=chunk) [Penalties and Rectifications](index=34&type=section&id=IX.%20Penalties%20and%20Rectification%20Status) During the reporting period, two subsidiaries received administrative penalties: Huludao He Eye Specialist Hospital was fined **RMB 3,000** for unapproved medical advertising, and Yingkou He Eye Specialist Hospital was fined **RMB 1,950** for unqualified personnel in the fire control room Administrative Penalties Received by Subsidiaries | Name/Entity | Reason | Conclusion (if any) | | :--- | :--- | :--- | | Huludao He Eye Specialist Hospital Co., Ltd. | Published medical advertisements without review | Fined RMB 3,000 | | Yingkou He Eye Specialist Hospital Co., Ltd. | Arranged unqualified personnel to be on duty in the fire control room | Fined RMB 1,950 | [Significant Related Party Transactions](index=34&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company did not engage in significant related party transactions concerning daily operations, asset or equity acquisitions/disposals, and has already forecasted and disclosed its routine related party transactions for 2024 - The company had no significant related party transactions during the reporting period concerning daily operations, asset or equity acquisitions/disposals, joint external investments, or related party debts and credits[88](index=88&type=chunk)[89](index=89&type=chunk)[90](index=90&type=chunk)[91](index=91&type=chunk) [Share Changes and Shareholder Information](index=38&type=section&id=Item%207%20Share%20Changes%20and%20Shareholder%20Information) This section details the company's share capital stability, the completion of its share repurchase program, and the composition of its shareholder base [Share Changes and Repurchase](index=38&type=section&id=1.%20Share%20Change%20Status) During the reporting period, the company's total share capital remained unchanged at **158,026,471 shares**, with **47.42%** restricted and **52.58%** unrestricted, and a share repurchase plan was completed, buying back **2,722,719 shares** for **RMB 67.50 million** - The company's total share capital remained unchanged at **158,026,471 shares** during the reporting period[99](index=99&type=chunk) - The company's share repurchase plan has been completed, with a cumulative repurchase of **2,722,719 shares**, representing **1.72%** of total share capital, at a total transaction amount of **RMB 67.50 million**[101](index=101&type=chunk) [Shareholder Information](index=39&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the reporting period end, the company had **9,650 common shareholders**, with controlling shareholders He Wei, He Xiangdong, and Fu Lifang (acting in concert) collectively holding **47.42%** of shares, alongside other major institutional investors - As of the reporting period end, the total number of common shareholders was **9,650**[102](index=102&type=chunk) Top Ten Shareholders | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | He Wei | 19.19% | 30,327,379 | | He Xiangdong | 11.51% | 18,196,428 | | Fu Lifang | 7.68% | 12,130,951 | | Advanced Manufacturing Industry Investment Fund (Limited Partnership) | 6.74% | 10,651,667 | | Dalian Neusoft Holdings Co., Ltd. | 4.96% | 7,831,435 | | Shenyang Siasun Robot & Automation Co., Ltd. | 4.96% | 7,831,435 | - He Wei, He Xiangdong, and Fu Lifang are parties acting in concert, jointly serving as the company's controlling shareholders and actual controllers[102](index=102&type=chunk) [Financial Report](index=45&type=section&id=Item%2010%20Financial%20Report) This section presents the company's unaudited consolidated and parent company financial statements, including detailed notes on key items, accounting policies, and related party transactions [Financial Statements](index=45&type=section&id=II.%20Financial%20Statements) This chapter provides the company's unaudited 2024 semi-annual consolidated and parent company financial statements, showing a decline in revenue and profit, and a slight contraction in total assets during the reporting period [Consolidated Balance Sheet](index=45&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of the reporting period end, total assets were **RMB 2.42 billion**, total liabilities **RMB 389 million**, and equity attributable to parent company owners **RMB 2.04 billion**, with monetary funds being a significant asset component and lease liabilities a major liability Consolidated Balance Sheet Highlights | Major Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | | :--- | :--- | :--- | | **Assets** | | | | Monetary Funds | 1,553,742,795.39 | 1,588,531,430.39 | | Fixed Assets | 263,852,887.53 | 210,440,134.44 | | **Total Assets** | **2,417,992,248.54** | **2,483,695,372.45** | | **Liabilities** | | | | Accounts Payable | 74,130,782.04 | 59,226,782.99 | | Lease Liabilities | 195,806,670.05 | 208,592,642.95 | | **Total Liabilities** | **388,684,298.40** | **411,355,038.30** | | **Owners' Equity** | | | | Total Owners' Equity Attributable to Parent Company | 2,036,002,056.42 | 2,075,313,837.01 | | **Total Owners' Equity** | **2,029,307,950.14** | **2,072,340,334.15** | [Consolidated Income Statement](index=49&type=section&id=3.%20Consolidated%20Income%20Statement) In the first half of 2024, the company's total operating revenue was **RMB 585 million**, a **5.84% year-on-year decrease**, leading to a significant **57.26% decline** in operating profit to **RMB 47.54 million**, and a **69.29% drop** in net profit attributable to parent company shareholders to **RMB 24.06 million** Consolidated Income Statement Highlights | Item | 2024 Half-Year (RMB) | 2023 Half-Year (RMB) | | :--- | :--- | :--- | | I. Total Operating Revenue | 584,757,474.76 | 620,995,594.44 | | II. Total Operating Costs | 537,327,702.87 | 511,996,840.09 | | Including: Operating Cost | 339,405,846.06 | 341,762,982.65 | | Selling Expenses | 88,130,582.43 | 78,031,673.84 | | Administrative Expenses | 108,177,561.58 | 96,268,350.59 | | Research and Development Expenses | 4,675,739.40 | 3,445,781.54 | | III. Operating Profit | 47,538,063.85 | 111,238,840.36 | | IV. Total Profit | 45,573,243.04 | 111,178,023.60 | | V. Net Profit | 20,343,364.12 | 76,652,128.97 | | Net Profit Attributable to Parent Company Shareholders | 24,063,967.54 | 78,347,857.61 | [Consolidated Cash Flow Statement](index=53&type=section&id=5.%20Consolidated%20Cash%20Flow%20Statement) During the reporting period, net cash flow from operating activities was **RMB 99.78 million**, a **10.33% year-on-year decrease**, with net cash outflows of **RMB 45.50 million** from investing and **RMB 89.46 million** from financing activities, resulting in a **RMB 35.18 million** net decrease in cash and cash equivalents Consolidated Cash Flow Statement Highlights | Item | 2024 Half-Year (RMB) | 2023 Half-Year (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 99,776,720.00 | 111,264,837.73 | | Net Cash Flow from Investing Activities | -45,499,710.14 | -59,617,152.38 | | Net Cash Flow from Financing Activities | -89,456,319.15 | -185,218,354.78 | | Net Increase/Decrease in Cash and Cash Equivalents | -35,179,111.85 | -133,519,405.05 | | Cash and Cash Equivalents at Period End | 1,552,289,860.85 | 1,504,506,028.67 | [Company Basic Information and Accounting Policies](index=62&type=section&id=III.%20Company%20Basic%20Information) This chapter details the company's history, registration, business scope, and outlines the basis for financial statement preparation, adherence to accounting standards, and significant accounting policies and estimates, providing a foundational framework for understanding financial data - The company prepares its financial statements on a going concern basis, adhering to enterprise accounting standards, with the functional currency being RMB[143](index=143&type=chunk)[144](index=144&type=chunk)[149](index=149&type=chunk) - Revenue recognition policy: Diagnosis and treatment service revenue is recognized when services are provided and fees are collected; optometry service revenue is recognized after providing fitting services and receiving payment or obtaining the right to receive payment[238](index=238&type=chunk)[241](index=241&type=chunk) - Impairment of financial instruments adopts the expected credit loss model, measuring loss provisions for accounts receivable and similar items based on expected credit losses over their entire lifetime[177](index=177&type=chunk) [Notes to Consolidated Financial Statement Items](index=101&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed notes on major consolidated financial statement items, including accounts receivable, other receivables, and inventory balances with their respective impairment provisions, as well as fixed assets, construction in progress, and key expense components like employee compensation Selected Asset Balances and Provisions | Item | Period-End Balance (RMB) | Bad Debt/Impairment Provision (RMB) | | :--- | :--- | :--- | | Accounts Receivable | 62,710,249.73 | 4,042,879.44 | | Other Receivables | 11,881,841.51 | 4,940,749.51 | | Inventory | 97,506,092.13 | 11,608,680.77 | Key Operating Expenses | Expense Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | | :--- | :--- | :--- | | Administrative Expenses | 108,177,561.58 | 96,268,350.59 | | Selling Expenses | 88,130,582.43 | 78,031,673.84 | | Research and Development Expenses | 4,675,739.40 | 3,445,781.54 | [Related Parties and Related Party Transactions](index=138&type=section&id=XIII.%20Related%20Parties%20and%20Related%20Party%20Transactions) The company's controlling shareholders and actual controllers are He Wei, He Xiangdong, and Fu Lifang, who as parties acting in concert, jointly control **47.42%** of the company's shares, with related party transactions including purchases of goods and services totaling **RMB 14.97 million** and property leases - The company's controlling shareholders and actual controllers are He Wei, He Xiangdong, and Fu Lifang, who are parties acting in concert, collectively controlling **47.42%** of the company's shares[355](index=355&type=chunk) Major Related Party Transactions (Purchases) | Related Party | Related Transaction Content | Current Period Amount (RMB) | | :--- | :--- | :--- | | Shenyang Ailuo Medical Supplies Co., Ltd. | Purchase of Goods and Acceptance of Services | 11,735,990.00 | | Shenyang Ailuo Intelligent Technology Co., Ltd. | Purchase of Goods and Acceptance of Services | 2,236,743.00 | | Shenyang Pacific Medical Supplies Manufacturing Co., Ltd. | Purchase of Goods | 592,915.00 | - The company leases properties and equipment from related parties for office, operational, and production purposes, recognizing corresponding lease expenses[363](index=363&type=chunk)

第三届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 八次会议于 2024 年 8 月 28 日在公司会议室以现场及通讯相结合的方式召开。会 议通知于 2024 年 8 月 18 日以邮件、电话等方式送达全体董事。会议由董事长何 伟先生主持，应出席董事 7 名，实际出席董事 7 名。公司监事及高级管理人员列 席了会议。本次会议的召集和召开符合《中华人民共和国公司法》等法律、法规、 规范性文件和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 证券代码：301103 证券简称：何氏眼科 公告编号：2024-030 辽宁何氏眼科医院集团股份有限公司 经与会董事审议，做出如下决议： （一）审议通过《关于<2024 年半年度报告>及其摘要的议案》 公司董事会在全面审核公司 2024 年半年度报告及摘要后，一致认为：公司 编制《公司 2024 年半年度报告全文及其摘要》的程序符合法律、行政法规和中 国证券监督管理委员会的有关规定，报告内容公 ...

中原证券股份有限公司关于 单位：万元 辽宁何氏眼科医院集团股份有限公司 使用部分闲置募集资金（含超募资金）及自有资金 进行现金管理的核查意见 中原证券股份有限公司（以下简称"中原证券"或"保荐机构"）作为辽宁 何氏眼科医院集团股份有限公司（以下简称"何氏眼科"、"公司"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指 引第 13 号——保荐业务》等有关规定，对何氏眼科使用部分闲置募集资金（含 超募资金）及自有资金进行现金管理的情况进行了审慎核查。核查情况及核查意 见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕126 号）同意注册，公司首 次公开发行人民币普通股（A 股）3,050.00 万股，每股面值 1 元，每股发行价格 为人民币 42.50 元，募集资金总额为人民币 129,625.00 万元，扣除与本次发行有 关的费用后募 ...

关于辽宁何氏眼科医院集团股份有限公司 2024 半年度持续督导跟踪报告 | 保荐机构名称：中原证券股份有限公司 | 被保荐公司简称：何氏眼科 | | --- | --- | | 保荐代表人姓名：钟坚刚 | 联系电话：010-57058322 | | 保荐代表人姓名：封江涛 | 联系电话：010-57058322 | 一、保荐工作概述 中原证券股份有限公司 三、公司及股东承诺事项履行情况 | 公司及股东承诺事项 | 是否履行承诺 | 未履行承诺的原因及解 决措施 | | --- | --- | --- | | 公司股东关于限售安排、自愿锁 定、延长锁定期限及减持意向的 | 是 | 不适用 | | 承诺 | | | | 稳定股价的措施和承诺 | 是 | 不适用 | | 对欺诈发行上市的股份回购承诺 | 是 | 不适用 | | 填补被摊薄即期回报的措施及承 | 是 | 不适用 | | 诺 | | | | 利润分配的承诺 | 是 | 不适用 | | 未履行承诺的约束措施 | 是 | 不适用 | 四、其他事项 | 报告事项 | 说 明 | | | | | | | | | --- | --- | --- | --- | ...

证券代码：301103 证券简称：何氏眼科 公告编号：2024-032 辽宁何氏眼科医院集团股份有限公司 2024年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》等规定， 将辽宁何氏眼科医院集团股份有限公司（以下简称公司）2024 年半年度募集资 金存放与使用情况报告如下： 二、募集资金存放和管理情况 一、募集资金基本情况 （一）募集资金金额和到账时间 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】126号）同意注册，公司首 次公开发行人民币普通股（A股）3,050.00万股，每股面值1元，每股发行价格为 人民币42.50元，募集资金总额为人民币129,625.00万元，扣除与本次发行有关的 费用后募集资金净额为人民币116,431. ...

辽宁何氏眼科医院集团股份有限公司 | | | | | 2024 年期初 | 2024 年 1-6 | 2024 年 月 1-6月份往 | | 2024 年 | 2024 年 | 6 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其它关联资金 | 资金往来方名称 | 往来方与上市公司的 | 上市公司核算 | 往来资金余 | 份往来累计发 | 来资金的 | | 1-6 月份 | 月末往来 | 往来形成 | （经营性往来、 | | 往来 | | 关联关系 | 的会计科目 | 额 | 生金额（不含利 | 利息（如 | | 偿还累计 | 资金余额 | 原因 | 非经营性往来） | | | | | | | 息） | 有） | | 发生金额 | | | | | | 辽宁睿目商贸有限公司 | 子公司 | 其他应收款 | 1.00 | | - | - | 1.00 | | - 往来款 | 非经营性往来 | | | 海南蜻蜓数字医疗科技有限公司 | 子公司 | 其他应收款 | 0.10 | | - | - ...